Study Number	AAML1331
NCT #	NCT02339740
Dataset #	D1
PMID#	34762093

Comments: Blanks represent missing data or not applicable for analyses.

Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for deidentification purposes or have undergone further data cleaning).

Variable Number	Variable Name	Туре	Label	Notes
1	USI	Char	Universal Specimen Identifier	
2	STRATUM	Char	AAML1331 Risk Group Stratum	
3	PCR_Exclusion	Char	Patient exclusion by not having PCR Positive	
4	P1_TRT	Char	Course 1 Therapy (Induction)	
5	P1_TRT_End	Char	Off (study/therapy) Reason (Induction)	
6	P1_WD_REASON	Char	Withdrew Reason (Induction)	
7	P2_TRT	Char	Course 2 Therapy (Consolidation Cycle 1)	
8	P2_TRT_End	Char	Off treatment Reason (Consolidation Cycle 1)	
9	P2_WD_REASON	Char	Withdrew Reason (Consolidation Cycle 1)	
10	P3_TRT	Char	Course 3 Therapy (Consolidation Cycle 1)	
11	P3_TRT_End	Char	Off treatment Reason (Consolidation Cycle 2)	
12	P3_WD_REASON	Char	Withdrew Reason (Consolidation Cycle 2)	
13	P3_end_Remission	Char	Remission Status (Consolidation Cycle 2)	
14	P4_TRT	Char	Course 4 Therapy (MRD Positive Consolidation)	
15	P5_TRT	Char	Course 5 Therapy (Consolidation Cycle 3)	
16	P5_TRT_End	Char	Off treatment Reason (Consolidation Cycle 3)	
17	P5_WD_REASON	Char	Withdrew Reason (Consolidation Cycle 3)	
18	P6_TRT	Char	Course 6 Therapy (Consolidation Cycle 4)	
19	Fup_Stats	Char	Follow Up Status	
20	Race_cat_	Char	Race Category	
21	Sex	Char	Sex	
22	ethn_cat	Char	Ethnicity	
23	APLTYPE	Char	APL morphology (M3v)	

Study Nu	ımber	AAML1331			
NCT#		NCT02339740			
Dataset #	:	D1			
PMID#		34762093			
Data can manuscri	be used to approximate posts may not be post	mate publish sible in som	ta or not applicable for analyses. led study findings, but exact reproduction of e cases (e.g., when data must be modified fo ne further data cleaning).	-	
24	Cyto_Complex	Char	Cytogenetic Complexity, t(15;17) with/without other Abnormalities		
25	ageyrs	Num	Age in Years		
26	ECOG	Num	ECOG Performance Status		
27	perifplt	Num	Peripheral platelet count (x1000/MicroLiter)		
28	wbc1	Num	White blood cell (WBC) Count (x1000/MicroLiter), at Diagnosis		
29	p1wbc	Num	Peripheral WBC Count (x1000/MicroLiter), Induction		
30	p1dys	Num	Course length in Days (Induction)		
31	p1ptcdx	Char	Was the patient diagnosed with pseudotumor cerebri during this reporting period? (Induction)		
32	p2ptcdx	Char	Was the patient diagnosed with pseudotumor cerebri during this reporting period? (Consolidation Cycle 1)		
33	рбрtсdх	Char	Was the patient diagnosed with pseudotumor cerebri during this reporting period? (Consolidation Cycle 4)		
34	osi	Num	Overall Survival (OS) beginning from study entry	0=censored, 1=death	
35	yrsos	Num	Years to OS from study entry		
36	efsi	Num	Event Free Survival (EFS) beginning from study entry	0=censored, 1=EFS event	
37	yrsefs	Num	Years to EFS from study entry		
38	rri1	Num	Relapse Risk (RR1) from End of Course 1 with Complete Remission indicator	0=censored, 1=relapse or induction failure, 2=competing event- death as first event	
39	yrsrr1	Num	Years Relapse Risk (RR1) from End of Course 1 with Complete Remission		
40	Death_Ind	Char	Induction Death		

Study Nu	ımber	AAML1331	[
NCT #		NCT02339740			
Dataset #		D1			
PMID#		34762093			
Data can manuscri	be used to approximate pts may not be pos	mate publish sible in som	ta or not applicable for analyses. ned study findings, but exact reproduction of e cases (e.g., when data must be modified for ne further data cleaning).	*	
41	dys_from_end_trt	Num	Follow Up Days from End of the Therapy		
42	CNSEVAL	Char	Was Central Nervous System (CNS) status evaluated prior to enrollment?		
43	CNSSTAT	Char	CNS Status		
44	Post_SCT	Char	Post Stem Cell Transplant Treatment		
45	CNS_Hemo	Char	CNS Hemorrhage		
46	ATRA_TRT	Char	Did patient receive pre-treatment with ATRA prior to administration of protocol therapy?		
47	Ind_Bleed_Thromb	Char	Did patient experience significant bleeding or thrombosis event? (Induction)?		
48	DS_Tot	Char	Differential Syndrome (DS)		
49	p1dysds	Num	Duration (Days) of treatment with dexamethasone therapy among patients with differentiation syndrome		
50	p1symp01	Num	Symptoms of DS - Respiratory distress	0=No, 1=Yes	
51	p1symp02	Num	Symptoms of DS - Hypoxemia	0=No, 1=Yes	
52	p1symp03	Num	Symptoms of DS - Fever	0=No, 1=Yes	
53	p1symp04	Num	Symptoms of DS - Erythematous rash	0=No, 1=Yes	
54	p1symp05	Num	Symptoms of DS - Pulmonary infiltrates	0=No, 1=Yes	
55	p1symp06	Num	Symptoms of DS - Pleural effusion	0=No, 1=Yes	
56	p1symp07	Num	Symptoms of DS - Pericardial effusion	0=No, 1=Yes	
57	p1symp08	Num	Symptoms of DS - Weight gain	0=No, 1=Yes	
58	p1symp09	Num	Symptoms of DS - Peripheral edema	0=No, 1=Yes	
59	p1symp10	Num	Symptoms of DS - Acute renal failure	0=No, 1=Yes	
60	p1symp11	Num	Symptoms of DS - Congestive heart failure	0=No, 1=Yes	

Study	udy Number AAML1331		331		
NCT :	#	NCT023	NCT02339740		
Datas	et#	D1	D1		
PMID) #	3476209	34762093		
Data o	can be used to appr scripts may not be	roximate publ possible in so	data or not applicable for analyses. lished study findings, but exact reprodu ome cases (e.g., when data must be mod gone further data cleaning).	-	
61	p1symp12	Num			
62	p1dyshosp	Num	Days in Hospital (Induction)		
63	p1dysicu	Num	Days in ICU (Induction)		
64	p2dyshosp	Num	Days in Hospital (Consolidation 1)		
65	p2dysicu	Num	Days in ICU (Consolidation 1)		
66	p3dyshosp	Num	Days in Hospital (Consolidation 2)		
67	p3dysicu	Num	Days in ICU (Consolidation 2)		
68	p5dyshosp	Num	Days in Hospital (Consolidation 3)		
69	p5dysicu	Num	Days in ICU (Consolidation 3)		
70	p6dyshosp	Num	Days in Hospital (Consolidation 4)		
71	p6dysicu	Num	Days in ICU (Consolidation 4)		